Table 3.
Uni- and multi-variate analysis of survival in patients with thymic malignancies
|
Univariate analysis | ||||||
|---|---|---|---|---|---|---|
|
Variants |
Thymoma
|
Thymic carcinoma
|
||||
| n | MST [95% CI] | p -value | n | MST [95% CI] | p -value | |
| Age (y) |
|
|
0.0018* |
|
|
0.36 |
| <70 |
91 |
71.3 [54.4-88.1] |
50 |
24.1 [13.5-43.6] |
||
| ≥70 |
28 |
30.1 [13.8-59.9] |
18 |
24.6 [11.9-36.4] |
||
| Gender |
|
|
0.29 |
|
|
0.076 |
| Male |
52 |
235.2 [136.8-NR] |
38 |
29.7 [13.5-40.2] |
||
| Female |
67 |
171.8 [110.1- NR] |
30 |
56.4 [23.7-73.0] |
||
| Masaoka-Koga Stage |
|
|
0.0012* |
|
|
0.18 |
| I |
52 |
NR [136.8- NR] |
0 |
- |
||
| II |
31 |
NR [NR - NR] |
6 |
78.9 [65.8-92.0] |
||
| III |
12 |
171.8 [4.7- NR] |
10 |
56.4 [8.8-99.6] |
||
| IVa |
18 |
110.1 [33.8-235.2] |
16 |
27.3 [17.2-43.9] |
||
| IVb |
6 |
83.8 [0.6- NR] |
36 |
21.6 [11.3-36.4] |
||
| Immunological abnormalities |
|
|
0.26 |
|
|
0.59 |
| Yes |
26 |
NR [171.8- NR] |
2 |
71.2 [69.5-73.0] |
||
| No |
93 |
156.6 [126.3- NR] |
66 |
30.4 [23.6-43.9] |
||
| Secondary Malignancies |
|
|
0.42 |
|
|
0.54 |
| Yes |
12 |
235.2 [74.4-235.2] |
13 |
36.8 [5.8-65.8] |
||
| No |
107 |
171.8 [136.8- NR] |
55 |
30.4 [21.6-56.4] |
||
| WHO classification [thymoma] |
|
|
0.68 |
|
|
|
| A |
5 |
79.2 [-] |
||||
| AB |
33 |
- [91.6- NR] |
||||
| B1 |
19 |
- [126.3- NR] |
||||
| B2 |
39 |
171.8 [110.1- NR] |
||||
| B3 |
15 |
- [37.2- NR] |
||||
| Other |
8 |
235.2 [4.4-235.2] |
||||
| [thymic carcinoma] |
|
|
|
|
|
0.95 |
| High grade |
52 |
36.8 [23.7-65.8] |
||||
| Low grade |
16 |
24.7 [8.5-66.6] |
||||
| Multivariate analysis | ||||||
| Variants |
Thymoma |
Thymic carcinoma |
||||
| |
HR |
95% CI |
P-value |
HR |
95% CI |
p-value |
| Staging |
IVa/ I: 4.62 |
[1.78-13.37] |
0.016* |
II/IVa: 0.27 |
[0.43-0.99] |
0.048* |
| |
IVa/II: 6.40 |
[2.03-28.17] |
0.001* |
|||
| |
IVb/II: 5.56 |
[1.02-30.20] |
0.047* |
|||
| Immunological abnormalities |
2.0 |
[0.73-6.35] |
0.18 |
|
|
|
| Secondary Malignancies |
4.4 |
[0.63-51.9] |
0.26 |
1.36 |
[0.57-3.28] |
0.44 |
| WHO Classification |
|
|
|
|
|
|
| (A/B1/B2/B3/AB/other) |
none |
none |
none |
- |
- |
- |
| (high grade vs. low grade) |
- |
- |
- |
0.88 |
[0.46-1.57] |
0.70 |
| (thymic ca. vs. thymoma) | 6.7 | 4.1-11.1 | < .0001* | - | - | - |
NR, not reached; CI, confidence interval; MST, median survival time; HR, hazard ratio; CI confidence interval; *p < 0.05.